|
1
|
Phillippe HM: Overview of venous
thromboembolism. Am J Manag Care. 23 (Suppl 20):S376–S382.
2017.PubMed/NCBI
|
|
2
|
Kyrle PA and Eichinger S: Deep vein
thrombosis. Lancet. 365:1163–1174. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Streiff MB, Agnelli G, Connors JM,
Crowther M, Eichinger S, Lopes R, McBane RD, Moll S and Ansell J:
Guidance for the treatment of deep vein thrombosis and pulmonary
embolism. J Thromb Thrombolysis. 41:32–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martinelli I, Bucciarelli P and Mannucci
PM: Thrombotic risk factors: Basic pathophysiology. Crit Care Med.
38 (Suppl 2):S3–S9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reitsma PH, Versteeg HH and Middeldorp S:
Mechanistic view of risk factors for venous thromboembolism.
Arterioscler Thromb Vasc Biol. 32:563–568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaheen K, Alraies MC, Alraiyes AH and
Christie R: Factor V Leiden: How great is the risk of venous
thromboembolism? Cleve Clin J Med. 79:265–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaplan D, Casper TC, Elliott CG, Men S,
Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA and
Rondina MT: VTE incidence and risk factors in patients with severe
sepsis and septic shock. Chest. 148:1224–1230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang
Z, Wan J, Liu P, Elalamy I and Wang C; Prevention Treatment of VTE
Associated with COVID-19 Infection Consensus Statement Group, :
Prevention and Treatment of Venous Thromboembolism Associated with
Coronavirus Disease 2019 Infection: A Consensus Statement before
Guidelines. Thromb Haemost. 120:937–948. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kartsios C, Lokare A, Osman H, Perrin D,
Razaq S, Ayub N, Daddar B and Fair S: Diagnosis, management, and
outcomes of venous thromboembolism in COVID-19 positive patients: A
role for direct anticoagulants? J Thromb Thrombolysis. Sep
10–2020.(Epub ahead of print). doi:
10.1007/s11239-020-02257-7.PubMed/NCBI
|
|
10
|
Tsatsakis A, Calina D, Falzone L, Petrakis
D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, et
al: SARS-CoV-2 pathophysiology and its clinical implications: An
integrative overview of the pharmacotherapeutic management of
COVID-19. Food Chem Toxicol. 146:1117692020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Branchford BR and Carpenter SL: The role
of inflammation in venous thromboembolism. Front Pediatr.
6:1422018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bovill EG and van der Vliet A: Venous
valvular stasis-associated hypoxia and thrombosis: What is the
link? Annu Rev Physiol. 73:527–545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Zhang Z, Wei R, Miao X, Sun S,
Liang G, Chu C, Zhao L, Zhu X, Guo Q, et al: IL (Interleukin)-6
contributes to deep vein thrombosis and is negatively regulated by
miR-338-5p. Arterioscler Thromb Vasc Biol. 40:323–334. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malaponte G, Polesel J, Candido S,
Sambataro D, Bevelacqua V, Anzaldi M, Vella N, Fiore V, Militello
L, Mazzarino MC, et al: IL-6-174 G>C and MMP-9-1562 C>T
polymorphisms are associated with increased risk of deep vein
thrombosis in cancer patients. Cytokine. 62:64–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma A, Singh K, Biswas A, Ranjan R,
Kishor K, Pandey H, Kumar R, Mahapatra M, Oldenburg J and Saxena R:
Impact of interleukin 6 promoter polymorphisms (−174 G>C, −572
G>C and −597 G>A) on plasma IL-6 levels and their influence
on the development of DVT: A study from India. Hematology.
23:833–838. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Dongen J, Jansen R, Smit D, Hottenga
JJ, Mbarek H, Willemsen G, Kluft C, Penninx BW, Ferreira MA,
Boomsma DI, et al AAGC Collaborators, : The contribution of the
functional IL6R polymorphism rs2228145, eQTLs and other genome-wide
SNPs to the heritability of plasma sIL-6R levels. Behav Genet.
44:368–382. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Müller-Newen G, Küster A, Hemmann U, Keul
R, Horsten U, Martens A, Graeve L, Wijdenes J and Heinrich PC:
Soluble IL-6 receptor potentiates the antagonistic activity of
soluble gp130 on IL-6 responses. J Immunol. 161:6347–6355.
1998.PubMed/NCBI
|
|
18
|
Scheller J and Rose-John S: The
interleukin 6 pathway and atherosclerosis. Lancet. 380:3382012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferreira RC, Freitag DF, Cutler AJ, Howson
JM, Rainbow DB, Smyth DJ, Kaptoge S, Clarke P, Boreham C, Coulson
RM, et al: Functional IL6R 358Ala allele impairs classical IL-6
receptor signaling and influences risk of diverse inflammatory
diseases. PLoS Genet. 9:e10034442013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morieri ML, Passaro A and Zuliani G:
Interleukin-6 ‘Trans-signaling’ and ischemic vascular disease: The
important role of soluble gp130. Mediators Inflamm.
2017:13963982017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saha P, Humphries J, Modarai B, Mattock K,
Waltham M, Evans CE, Ahmad A, Patel AS, Premaratne S, Lyons OT, et
al: Leukocytes and the natural history of deep vein thrombosis:
Current concepts and future directions. Arterioscler Thromb Vasc
Biol. 31:506–512. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bevelacqua V, Libra M, Mazzarino MC,
Gangemi P, Nicotra G, Curatolo S, Massimino D, Plumari A, Merito P,
Valente G, et al: Long pentraxin 3: A marker of inflammation in
untreated psoriatic patients. Int J Mol Med. 18:415–423.
2006.PubMed/NCBI
|
|
24
|
Malaponte G, Libra M, Bevelacqua Y, Merito
P, Fatuzzo P, Rapisarda F, Cristina M, Naselli G, Stivala F,
Mazzarino MC, et al: Inflammatory status in patients with chronic
renal failure: The role of PTX3 and pro-inflammatory cytokines. Int
J Mol Med. 20:471–481. 2007.PubMed/NCBI
|
|
25
|
Signorelli SS, Anzaldi M, Fiore V, Simili
M, Puccia G, Libra M, Malaponte G and Neri S: Patients with
unrecognized peripheral arterial disease (PAD) assessed by
ankle-brachial index (ABI) present a defined profile of
proinflammatory markers compared to healthy subjects. Cytokine.
59:294–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Signorelli SS, Anzaldi M, Libra M,
Navolanic PM, Malaponte G, Mangano K, Quattrocchi C, Di Marco R,
Fiore V and Neri S: Plasma levels of inflammatory biomarkers in
peripheral arterial disease: Results of a Cohort Study. Angiology.
67:870–874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Signorelli SS, Candido S, Salemi R, Fiore
V, Mangiafico M and Libra M: Low levels of inflammation and the
absence of subclinical atherosclerosis in rheumatoid arthritis. Mol
Med Rep. 13:3521–3524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hunter CA and Jones SA: IL-6 as a keystone
cytokine in health and disease. Nat Immunol. 16:448–457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kang S, Tanaka T, Narazaki M and Kishimoto
T: Targeting interleukin-6 signaling in clinic. Immunity.
50:1007–1023. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saghazadeh A and Rezaei N: Inflammation as
a cause of venous thromboembolism. Crit Rev Oncol Hematol.
99:272–285. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Libra M, Signorelli SS, Bevelacqua Y,
Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F,
Mazzarino MC and Malaponte G: Analysis of G(−174)C IL-6
polymorphism and plasma concentrations of inflammatory markers in
patients with type 2 diabetes and peripheral arterial disease. J
Clin Pathol. 59:211–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pennisi M, Lanza G, Falzone L, Fisicaro F,
Ferri R and Bella R: SARS-CoV-2 and the nervous system: From
clinical features to molecular mechanisms. Int J Mol Sci.
21:54752020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Papa A, Di Dato MT, Buonavolonta P,
Saracco E, Salzano AM and Casale B: Clinical management of Il-6
driven cytokine storm related to COVID-19 in a patient with recent
spinal cord stimulator implants: A Case Report. Anesth Pain Med.
10:e1041512020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vivarelli S, Falzone L, Grillo CM,
Scandurra G, Torino F and Libra M: Cancer management during
COVID-19 pandemic: Is immune checkpoint inhibitors-based
immunotherapy harmful or beneficial? Cancers (Basel). 12:22372020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vivarelli S, Falzone L, Torino F,
Scandurra G, Russo G, Bordonaro R, Pappalardo F, Spandidos DA,
Raciti G and Libra M: Immune-checkpoint inhibitors from cancer to
COVID 19: A promising avenue for the treatment of patients with
COVID 19 (Review). Int J Oncol. 58:145–157. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng M, Wang X, Guo H, Fan Y, Song Z, Lu
Z, Wang J, Zheng C, Dong L, Ma Y, et al: The Cytokine profiles and
immune response are increased in COVID-19 patients with type 2
diabetes mellitus. J Diabetes Res. 2021:95267012021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaur S, Bansal R, Kollimuttathuillam S,
Gowda AM, Singh B, Mehta D and Maroules M: The looming storm: Blood
and cytokines in COVID-19. Blood Rev. 46:1007432021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shayevitch R, Askayo D, Keydar I and Ast
G: The importance of DNA methylation of exons on alternative
splicing. RNA. 24:1351–1362. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lev Maor G, Yearim A and Ast G: The
alternative role of DNA methylation in splicing regulation. Trends
Genet. 31:274–280. 2015. View Article : Google Scholar : PubMed/NCBI
|
